Home Tags RC118

Tag: RC118

Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021

Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, said it will prioritize key research and development efforts to advance EO-3021 (SYSA1801), its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin 18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.

RC118 Targeting Claudin 18.2 ADC Receives Two Orphan Drug Designations

RC118, an antibody-drug conjugates or ADC being developed by RemeGen, a commercial-stage biotechnology company based in Yantai, China, has been granted two orphan drug...